#15 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Cannabis rescheduling could ease research restrictions and reduce tax burdens on the industry, but it won’t make recreational marijuana legal—only Congress can do that.
Reform advocates are watching Attorney General Pam Bondi’s scheduled appearance before the House Judiciary Committee for an update on where cannabis rescheduling stands. Pennsylvania House Democrats are calling on the GOP Senate to follow their lead on legalization, as Gov. Shapiro called for it in his budget. Ohio cannabis operators are split on a referendum to block marijuana and hemp restrictions. Nevada cannabis sales generated nearly $96M for the State Education Fund in FY2025.
“Rescheduling is a step forward for research and tax relief, but let’s be clear: it changes the category on a form, not the reality on the ground for patients and businesses.”
BANKING AND HEMP: THE FINANCIAL INFRASTRUCTURE CRISIS NO ONE’S TALKING ABOUT
The hemp industry’s banking problems didn’t start with the November ban, but they’re about to get dramatically worse.
Even under the 2018 Farm Bill, hemp businesses faced persistent banking challenges. Financial institutions struggled to distinguish between legal hemp operations and illegal cannabis activity. Many banks simply refused hemp accounts altogether, citing compliance risk.
The November ban transforms this from an inconvenience into an existential threat. After the law takes effect, any hemp-derived cannabinoid product exceeding 0.3% total THC—including intermediate products during manufacturing—becomes a controlled substance. Banks that continue servicing these businesses face potential money laundering liability.
The SAFE Banking Act, which would have protected financial institutions serving state-legal cannabis businesses, has repeatedly failed to pass. Without it, hemp cannabinoid companies face the same banking desert that has plagued the marijuana industry for years.
Payment processors are already pulling back. Several major processors quietly dropped hemp CBD merchants in late 2025 and early 2026, citing regulatory uncertainty. Shopify and Square have tightened their hemp product policies.
For small and mid-sized hemp businesses, this may be the ban’s most immediate practical impact—not FDA enforcement or DEA raids, but simply losing the ability to accept credit cards and maintain business bank accounts.
Have thoughts on this? Share it:
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →